Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma ...
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, shared her thoughts on the current research regarding Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2) inhibitors in chronic ...
Use of tumor-mediated TRAIL-receptor expression to evaluate apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer. SPARC microenvironment signature (SMS) in patients ...
BUFFALO, NY- September 1, 2022 – A new research paper was published in Aging ("Aging (Albany NY)" by Medline/PubMed, "Aging-US" by Web of Science) on the cover of Volume 14, Issue 16, entitled, ...
A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure. This is an ASCO Meeting Abstract from the 2023 ASCO ...
The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...
A novel, fixed-duration drug combination — consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug — shows ...
China’s National Medical Products Administration approved Ascentage Pharma Group Corp. Ltd.’s Bcl-2 selective inhibitor lisaftoclax (APG-2575) for treating adults with chronic lymphocytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results